Search Results 361-370 of 16908 for Amphotericin B
AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center, open-label study ...
Narrow your search · There are no doctors whose last name begins with the letter A A · Find a doctor whose last name begins with the letter B B · There are no ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...
Make your tax-deductible gift and be part of the cutting-edge research and care that's changing medicine. Donate.
Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day ... A Study ...
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study. Am J Hematol. 2025 Apr; 100 (4):606-615 ...
Narrow your search · Find a doctor whose last name begins with the letter A A · Find a doctor whose last name begins with the letter B B · Find a doctor whose last ...
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers.
Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.